LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Închisă

SectorSănătate

87.41 0.59

Rezumat

Modificarea prețului

24h

Curent

Minim

87.23

Maxim

87.41

Indicatori cheie

By Trading Economics

Venit

16M

1.3B

Vânzări

-111M

8.3B

P/E

Medie Sector

23.197

51.198

EPS

1.62

Randament dividend

3.39

Marjă de profit

15.605

Angajați

95,000

EBITDA

-42M

2.4B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+10.07% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.39%

2.40%

Următoarele câștiguri

19 aug. 2025

Data viitoare de dividende

11 iul. 2025

Următoarea dată ex-dividende

27 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-13B

107B

Deschiderea anterioară

86.82

Închiderea anterioară

87.41

Sentimentul știrilor

By Acuity

26%

74%

68 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Medtronic PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 mai 2025, 11:38 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18 feb. 2025, 12:24 UTC

Câștiguri

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21 mai 2025, 17:23 UTC

Top știri
Achiziții, Fuziuni, Preluări

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 mai 2025, 11:39 UTC

Top știri
Achiziții, Fuziuni, Preluări

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 mai 2025, 10:52 UTC

Câștiguri

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 mai 2025, 10:51 UTC

Câștiguri

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 mai 2025, 10:50 UTC

Câștiguri

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 mai 2025, 10:49 UTC

Câștiguri

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21 mai 2025, 10:49 UTC

Câștiguri

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21 mai 2025, 10:48 UTC

Câștiguri

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21 mai 2025, 10:48 UTC

Câștiguri

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21 mai 2025, 10:47 UTC

Câștiguri

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21 mai 2025, 10:45 UTC

Achiziții, Fuziuni, Preluări

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Net $1.06B >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Diabetes Rev $728M >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Adj EPS $1.62 >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q EPS 82c >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21 mai 2025, 10:45 UTC

Câștiguri

Medtronic 4Q Sales $8.93B >MDT

21 mai 2025, 09:00 UTC

Top știri
Achiziții, Fuziuni, Preluări

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21 mai 2025, 09:00 UTC

Achiziții, Fuziuni, Preluări

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21 mai 2025, 09:00 UTC

Achiziții, Fuziuni, Preluări

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21 mai 2025, 09:00 UTC

Achiziții, Fuziuni, Preluări

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27 feb. 2025, 10:30 UTC

Top știri

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 feb. 2025, 11:47 UTC

Câștiguri

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 feb. 2025, 11:46 UTC

Câștiguri

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Comparație

Modificare preț

Medtronic PLC Așteptări

Obiectiv de preț

By TipRanks

10.07% sus

Prognoză pe 12 luni

Medie 95.76 USD  10.07%

Maxim 109 USD

Minim 87 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMedtronic PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

21 ratings

11

Cumpărare

10

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

83.26 / 84.875Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

68 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.